Navigation Links
Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
Date:1/31/2008

Thursday, February 7th, 11:00 a.m. EST

WALTHAM, Mass., Jan. 31 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, February 7th, 2008 at 11:00 a.m. EST, to report third quarter fiscal year 2008 financial results and to provide a quarterly update of the Company.

This call is being webcast by Thomson/CCBN and can be accessed via Repligen's website at http://www.repligen.com. If you are unable to access the webcast via the internet, you may also listen to the live broadcast by calling (888) 713-4216 for domestic calls and (617) 213-4868 for international calls. Participants must provide the following passcode: 98169734. For those who cannot participate in the live conference call, an archive of the audio webcast will be available shortly after the call and may be accessed at http://www.repligen.com.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from http://www.repligen.com.

This press release contains forward-looking statements which ar
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Hologic Announces First Quarter Fiscal 2008 Operating Results
3. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
4. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
5. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
6. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Genelabs Technologies, Inc. Announces Resignation of President and CEO
9. CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board
10. BioHorizons Announces Agreement to Purchase Implant Logic Systems
11. AlphaVax Announces New CMV Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January ... company developing antibody-drug conjugates for cancer, today announced the appointment ... Directors. Dr Reynolds has over 20 years, development experience gained ... at Seattle Genetics. "I am delighted to welcome ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and mathematics ... competition for middle and high school students designed to ... The competition presents students with real-world problems experienced by ... and Sciences is a program administered by the ...
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... WASHINGTON , Jan. 14, 2014  3D Communications, a leading provider ... scientific, regulatory, business, and media events in the United ... its former associate Virginia Cox , JD, is returning to ... Virginia Cox re-joins 3D after more than two years ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... Data Reported by Roche at 69th Scientific Sessions , ... Inc. (Nasdaq: VIAP ), a biotechnology company ... of cardiovascular and metabolic disease, announced today that preclinical ... inhibitors will be presented in a poster presentation at ...
... , Thursday, June 11th, 10:00 a.m. EDT , , ... ) announced today that the Company President and Chief Executive Officer, ... on Thursday, June 11th, 2009 at 10:00 a.m. EDT, to report ... a quarterly update of the Company. , , This call ...
... initial steps towards producing Influenza A (H1N1) VLP vaccine for ... 4 Novavax, Inc. (Nasdaq: NVAX ) and ... National Institute of Allergy and Infectious Diseases (NIAID), National Institutes ... the evaluation of a virus-like particle (VLP) vaccine candidate against ...
Cached Biology Technology:VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 2VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 4Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results 3Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 2Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 3Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 4
(Date:4/23/2014)... Wash. -- Like a hungry diner ripping open a ... into electricity must tear open a hydrogen molecule. Now ... holding onto the two halves of its hydrogen feast. ... how to make the catalyst work better for alternative ... scientists have shown precisely where the hydrogen halves end ...
(Date:4/23/2014)... Putnam Valley, NY. (Apr. 23 2014) ... human neural stem cells (hNSCs) into the brains ... differentiation after 22 and 24 months found that ... months and did not cause tumors. , The ... of Cell Transplantation but is currently ...
(Date:4/23/2014)... evidence of an interaction between prenatal smoking and ... children, especially in girls. , "The interesting issue ... smoking will have behavioral problems. Some might, ... Professor at Sam Houston State University, College of ... "One possible explanation for this is that ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Study finds long-term survival of human neural stem cells transplanted into primate brain 2Genetics risk, prenatal smoking may predict behavioral problems 2
... we are strong and healthy and then we weaken and die ... about. But, in nature, the phenomenon of ageing shows an unexpected ... The University of Southern Denmark. Not all species weaken ... get stronger and less likely to die with age, while others ...
... The addition of a monoclonal antibody called gemtuzumab combined ... the risk of relapse and increase rates of disease-free ... Post-treatment relapse rates are a major indicator of potential ... The study (abstract #355) evaluated a total of 1,022 ...
... EPA grant, NJIT established its Technical Assistance to Brownfield ... allow NJIT to continue to provide communities with scientific, ... Specifically, the grant allows the NJIT TAB team to ... Mid-Atlantic region. NJIT TAB is comprised of planners, environmental ...
Cached Biology News:Surprising diversity in aging revealed in nature 2Surprising diversity in aging revealed in nature 3Targeted treatment can significantly reduce relapse in children with AML leukemia 2EPA awards $1 million grant to NJIT's Brownfield program 2